Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Kirsten Thompson Partner, Dentons As a technology and then privacy lawyer, Kirsten Thompson recognised the importance of data early on....
...Lentz joins from Thompson & Knight. Latham & Watkins has hired Meghan Cocci as a partner in the law firm’s corporate department....
...US drugmaker Pfizer has won its appeal against an £84.2m fine imposed by the UK’s competition regulator for sharply increasing the price of an epilepsy drug....
...We have Pfizer, we have Chiesi, we have [AstraZeneca] . . .[ and] Bohringer Ingelheim in this COPD space with huge amounts to offer and huge skin in the game.”...
...Thompson, a Briton who also chairs UK private equity group 3i, will take up the position in March, when Jan du Plessis steps down....
...star Regulatory oversight has not kept up with growth in premiums Indian banks: power to the consumer Private-sector lenders exposed to the consumer sector should outperform European takeovers: Macron v...
...Pfizer, for example, raised the price of 148 drugs, including Viagra, its erectile dysfunction treatment, and Lyrica, for nerve pain....
...Erik Nordkamp, UK managing director for Pfizer, said even crisis-hit Greece had wider access to the latest treatments....
...However, Terrence Thompson, a tax expert at Credit Suisse, recently told investors in the pharmaceuticals sector that he found their silence worrying, warning that they could be planning more drastic measures...
...The rebuffing of the bid made life harder for Aerojet, Mr Thompson added....
...While drugmakers in the US and Europe are engaged in a feverish ritual of courtship – and rejections, culminating in Pfizer’s thwarted £69.4bn bid for AstraZeneca – Japan’s last wave of major pharmaceutical...
...“We are going to create medicines that measure,” says chief executive Andrew Thompson....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...ULA has stockpiled two years’ worth of RD180s for launches – and could switch more launches from the Atlas V to its more old-fashioned but wholly US-sourced Delta rockets....
...are holding up at Nomura Holdings when it announces second-quarter results on Tuesday, after Japan’s largest brokerage last reported a bumper set of results for the three months to June, writes Jennifer Thompson...
...The four top Democrats – Ms Quinn, public advocate Bill de Blasio, city comptroller John Liu and former comptroller William Thompson – have raised more than $16m....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...CA Inc climbed 9.6 per cent to $25.02 as the software developer easily beat analyst expectations....
...Cheaper copies of Lipitor, Pfizer’s best-selling cholesterol drug, which had sales of $11.4bn in 2009, will enter the market next year and like many pharmaceutical groups facing similar threats, Pfizer has...
...The S&P 500 in New York rose 0.4 per cent to a five month high as traders welcomed the Fed’s minutes and news of another M&A deal – this time Pfizer’s purchase of King Pharma for $3.6bn....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
International Edition